We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma. Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, which results in irreversible vision loss and potentially blindness. Patients may suffer the adverse effects of glaucoma across a wide range of IOP levels. Our product candidates, Triple-action Rhopressa™ and Quadruple-action Roclatan™, are once-daily eye drops that, if approved, will provide eye-care professionals with the first novel intraocular pressure-lowering mechanisms of action, or MOA, to treat glaucoma in nearly 20 years.
Oct 28, 2014
Aerie Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014
Oct 6, 2014
Aerie Pharmaceuticals Elects Benjamin F. McGraw, III to Its Board of Directors
View all »Events & Presentations
Nov 11, 2014 at 5:00 PM ET
Aerie Pharmaceuticals, Inc. Third Quarter 2014 Earnings Call